All authors contributed equally. A. Zumla, D. Asogun, and C. Ihekweazu are members of the PANDORA-ID-NET Consortium. PANDORA-ID-NET (EDCTP Reg/Grant RIA2016E-1609) is funded by the European and Developing Countries Clinical Trials Partnership (EDCTP2) programme, which is supported under Horizon 2020, the European Union's Framework Programme for Research and Innovation. A. Zumla is in receipt of a National Institutes of Health Research senior investigator award. Conflicts of Interest: All authors have an interest in global public health and emerging and reemerging infections. All authors have no other conflict of interest to declare.

The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected. We describe the clinical picture and laboratory findings 3–23 days since the first symptoms. The SARS-CoV-2/Finland/1/2020 virus strain was isolated, the genome showing a single nucleotide substitution to the reference strain from Wuhan. Neutralising antibody response appeared within 9 days along with specific IgM and IgG response, targeting particularly nucleocapsid and spike proteins.

Colonized travelers contribute to the pandemic spread of resistant intestinal bacteria. This study is the first to show that antimicrobial use during travel predisposes to colonization by intestinal extended-spectrum beta-lactamase-producing Enterobacteriaceae. Travelers refrain from taking unnecessary antibiotics.